Home › Veracyte Q2 Revenues Rise 23 Percent

Veracyte Q2 Revenues Rise 23 Percent

Aug 03, 2016

This article has been updated to clarify Veracyte's copromotion arrangement with Sanofi Genzyme.

NEW YORK (GenomeWeb) – Veracyte announced after the close of the market Wednesday a 23 percent rise in its second quarter revenues as the company continued to experience increased demand for its Afirma gene expression classifier thyroid test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

What's Popular?

In Molecular Diagnostics

  1. Thermo Fisher Scientific Q2 Revenues Up 10 Percent; Firm Increases 2017 Guidance Again

  2. Nanopore Sequencing, PCR Platforms Evaluated for Rapid Pneumonia Diagnosis in UK Study

    Premium

  3. Exact Sciences Q2 Revenues Up 172 Percent

  4. Genomic Vision 1H 2017 Revenues Up 15 Percent

  5. Roche Includes Cobas HIV-1/HIV-2 Test in Global Access Program

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.